| Effects of Oral Adsorbent AST-120 (Kremezin®) on the Progression of Chronic Kidney Disease |
| Yong Kyu Lee, M.D., Sung Jin Moon, M.D., Hye Rim An, M.D., Jwa Kyung Kim, M.D., Sung Chang Bae, M.D., Beom Seok Kim, M.D., Hyeong Cheon Park, M.D. and Sung Kyu Ha, M.D. |
| Department of Internal medicine, Yonsei University College of Medicine, Seoul, Korea |
| 원저 : Effects of Oral Adsorbent AST-120 (Kremezin®) on the Progression of Chronic Kidney Disease |
| Yong Kyu Lee, M.D., Sung Jin Moon, M.D., Hye Rim An, M.D., Jwa Kyung Kim, M.D., Sung Chang Bae, M.D., Beom Seok Kim, M.D., Hyeong Cheon Park, M.D. and Sung Kyu Ha, M.D. |
| Department of Internal medicine, Yonsei University College of Medicine, Seoul, Korea |
|
|
| Abstract |
|
Purpose: AST-120 is known to delay progression of chronic kidney disease (CKD) when combined with other proven therapy. AST-120 is an oral adsorbent for uremic toxin, such as indoxyl sulfate from the gastrointestinal tract. There have been a lot of studies to show its effect in other countries, but there are few studies done in Korea yet.
Methods: 195 patients were included in the study (mean age, 64±14 years; diabetes mellitus (DM), 104 patients; male, 130 patients). The patients with CKD who started AST-120 and maintained the medication for at least 6 months were enrolled. The patients’ laboratory results for 6 months before and after administrating AST-120 was surveyed. Then the rate of patients’ renal functional deterioration was compared before and after AST-120. In addition, adverse effects during the medication were surveyed.
Results: There were no statistically significant differences in laboratory data between before and after AST-120 administration. But, after administrating AST-120, the renal deterioration slope has blunted significantly from -0.0123±0.0318 to -0.0013±0.0184 dL/mg/month (p<0.01) in 1/sCr and from -1.1423±2.3906 to 0.0639±1.3825 ml/min/1.73m2/month (p<0.01) in estimated glomerular filtration rate (eGFR). There were no differences between DM and non-DM patients in the effect of AST-120, as well as ages over 70 and below 70. There were no serious adverse effects during medication.
Conclusion: This study showed that AST-120 had additive effect on retarding the CKD progression when combined with established therapy regardless of DM and ages without serious adverse effects. |
| Key Words:
AST-120, Chronic renal failure, Glomerular filtration rate |
|
PDF Links
Download Citation
